Tomoyuki Igawa, Ph.D., graduated and was awarded Ph.D. from the University of Tokyo for studies in Engineering, Chemistry, and Biotechnology. Dr. Igawa started his career at Chugai Pharmaceutical, a member of the Roche group, and has led the effort to develop novel antibody engineering technologies, such as bispecific antibody for Hemlibra® (emicizumab), recycling antibody for Enspring® (satralizumab), half-life extension technology for Mitchga® (nemolizumab), and other various technologies applied to Chugai/Roche pipeline products.

After serving as CEO and Research Head of Chugai Singapore, Dr. Igawa was the Head of Translational Research Division in Chugai Pharmaceutical, responsible for early clinical development. He is currently the Associate Vice President, Head of Translational Research at Chugai. Dr. Igawa has published > 40 peer reviewed papers and is an inventor of > 90 patents in antibody drug discovery.